We Take A Look At Whether GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) CEO May Be Underpaid

Key Insights

• GlaxoSmithKline Pharmaceuticals will host its Annual General Meeting on 27th of June
• CEO Bhushan Akshikar's total compensation includes salary of ₹16.0m
• Total compensation is 56% below industry average
• Over the past three years, GlaxoSmithKline Pharmaceuticals' EPS grew by 35% and over the past three years, the total shareholder return was 140%

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

The solid performance at GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) has been impressive and shareholders will probably be pleased to know that CEO Bhushan Akshikar has delivered. At the upcoming AGM on 27th of June, they will get a chance to hear the board review the company results, discuss future strategy and cast their vote on any resolutions such as executive remuneration. We think the CEO has done a pretty decent job and probably deserves a well-earned pay rise.

See our latest analysis for GlaxoSmithKline Pharmaceuticals

Comparing GlaxoSmithKline Pharmaceuticals Limited's CEO Compensation With The Industry

Our data indicates that GlaxoSmithKline Pharmaceuticals Limited has a market capitalization of ₹543b, and total annual CEO compensation was reported as ₹68m for the year to March 2025. This means that the compensation hasn't changed much from last year. While this analysis focuses on total compensation, it's worth acknowledging that the salary portion is lower, valued at ₹16m.

In comparison with other companies in the Indian Pharmaceuticals industry with market capitalizations ranging from ₹346b to ₹1.0t, the reported median CEO total compensation was ₹154m. This suggests that Bhushan Akshikar is paid below the industry median.

Talking in terms of the industry, salary represented approximately 99% of total compensation out of all the companies we analyzed, while other remuneration made up 0.89343488% of the pie. It's interesting to note that GlaxoSmithKline Pharmaceuticals allocates a smaller portion of compensation to salary in comparison to the broader industry. If total compensation is slanted towards non-salary benefits, it indicates that CEO pay is linked to company performance.

A Look at GlaxoSmithKline Pharmaceuticals Limited's Growth Numbers

GlaxoSmithKline Pharmaceuticals Limited's earnings per share (EPS) grew 35% per year over the last three years. It achieved revenue growth of 8.6% over the last year.

Shareholders would be glad to know that the company has improved itself over the last few years. It's nice to see revenue heading northwards, as this is consistent with healthy business conditions. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.

Has GlaxoSmithKline Pharmaceuticals Limited Been A Good Investment?

Boasting a total shareholder return of 140% over three years, GlaxoSmithKline Pharmaceuticals Limited has done well by shareholders. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.

To Conclude...

Seeing that the company has put in a relatively good performance, the CEO remuneration policy may not be the focus at the AGM. In fact, strategic decisions that could impact the future of the business might be a far more interesting topic for investors as it would help them set their longer-term expectations.

While it is important to pay attention to CEO remuneration, investors should also consider other elements of the business. That's why we did some digging and identified 1 warning sign for GlaxoSmithKline Pharmaceuticals that you should be aware of before investing.

Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.